NEW RESEARCH—In a retrospective cohort study, frailty—an approximation of biological age—was a risk factor for severe infection in older adults with ANCA-associated #vasculitis https://t.co/TKNRzHswDv @SattuiSEMD @zach_wallace_md
22nd International Vasculitis Workshop, Melbourne 2026
The biggest and definitive biannual meeting of the #Vasculitis Research, Clinical and Patient Community
Go to https://t.co/vm7b0TFlI5 to register your interest. More to follow.
See you in Melbourne in the southern summer!
If you missed our May webinary "Tools for Improving the Diagnosis of GCA" with Dr. JP Makhzoum, DR. Junek and Dr. Seidman, no problem! You can view it (along with our other webinars) online now on the CanVasc Website: https://t.co/ZjSh33qYgk
Congratulations to HEI student @ArnavAgarwalMD who received the 2024 Vanier Canada Graduate Scholarship! Arnav is completing his PhD in Health Research Methodology under supervisor @GuyattGH, HEI Professor.
🔗 Learn more about his research: https://t.co/N31Ld4dqD9 @machealthsci
I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something & good safety during trial.
Would love to eventually see:
- H2H comparative effect vs toci, secukinumab
- structural outcomes
- long-term safety
#EULAR2024 PBA0001 @RheumNow
📢Save the date for the upcoming @can_vasc webinar on the topic of Tools for Improving the Diagnosis of GCA, presented by Dr. Makhzoum, @MatsJunek, and @MSeidmanMD
Registration opening soon!
We would love you to join us for the next Vasculitis Workshop. Hosted by @anzvasc. Co-convenors @KitchingLab@VickiQuincey and yours truly. Please DM if you have great ideas for us to incorporate into the next workshop #vasculitis
post hoc of the PEXIVAS study 704 participants w/ severe ANCA vasculitis: 92% achieved remission & 23% had relapses (rate 10.3/100PYs)-- Neither plasma exchange nor glucocorticoid tapering regimen impacted relapse risk. https://t.co/UN6RujwZKc
We're delighted to publish the first articles in our new 'Current and future advances in practice' series. Brain child of the fab @drdavidliew, this series aims to provide practical reviews of topics typically underrepresented by the literature ✨ 🧵
https://t.co/2zsifyYzlp
#ACR23 Plenary Abs #1584: TMP-SMX PPx associated w/ subsequent reduced serious and overall infections in RTX-treated GPA. Now to understand what is optimization of PPx for these pts. https://t.co/O8WE1pslzC @rheumnow
Thrilled to share our new editorial co-authored with my amazing mentors @EBRheum and @MatsJunek!
We discuss the limitations of the ADVOCATE trial and the importance of using modern standards of care in rheumatology trials.
Read more here: https://t.co/trfXoVsKIp
Some thoughts on the ADVOCATE trial, great time working with @MatsJunek & @sharanyakaushik on this project. Already used the excellent diagram Sharanya put together in a talk!